Oliver Wyman

Although there are 155 million registered donors or nearly half of US adults, transplant waitlists remain long. While the US leads the world in deceased organ donation rates with steady growth and clinical innovations that have helped address the need, there is major room for improvement. Says Alex Glazier, CEO of New England Donor Services, with the right systemwide interventions, deceased donor kidney transplantation could jump by 61% by 2026. Dan Shellenbarger, Partner in Oliver Wyman's Health and Life Sciences Practice, sat down with Alex Glazier, CEO of New England Donor Services, and Kevin O'Connor, CEO of LifeCenter Northwest on the Oliver Wyman Health Podcast to talk about ways in which their organizations are driving improvements in organ recovery and transplantation and why older donors are a key demographic of focus. For more information, follow us on Twitter @OWHealthEditor, read our online healthcare publication, Oliver Wyman Health, at health.oliverwyman.com, and see our guest roster: oliverwyman.com/oliverwymanhealthpodcast. Questions or comments? Email Oliver Wyman Health's Editor, matthew.weinstock@oliverwyman.com.

Organ Donation and Recovery: What You Don’t Know May Surprise You

Blog

Health and Life Sciences Practice

The Oliver Wyman Health Podcast features conversations with leaders who are pioneering the transformation of the health market. Oliver Wyman’s Health & Life Sciences Practice is a leader in value-based, consumer-centric healthcare, and serves clients in the pharmaceutical, biotechnology, medical devices, provider, and payer sectors. Topics covered in this series include the business challenges of transforming healthcare from volume to value, consumer engagement, consumer experience, digital health, care delivery models, strategy, leadership, and organization.
Oliver Wyman is a global leader in management consulting that combines deep industry knowledge with specialized expertise in strategy, operations, risk management, and organization transformation. Oliver Wyman is a wholly owned subsidiary of Marsh & McLennan Companies [NYSE: MMC].